$11.92
4.56% yesterday
Nasdaq, Aug 12, 10:17 pm CET
ISIN
KYG8807B1068
Symbol
TBPH

Theravance Biopharma Inc Stock price

$11.92
+0.45 3.92% 1M
+2.56 27.35% 6M
+2.51 26.67% YTD
+3.68 44.66% 1Y
+2.31 24.04% 3Y
-4.89 29.09% 5Y
-0.32 2.61% 10Y
-11.04 48.08% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.52 4.56%
ISIN
KYG8807B1068
Symbol
TBPH
Industry

Key metrics

Basic
Market capitalization
$570.0m
Enterprise Value
$470.1m
Net debt
positive
Cash
$130.9m
Shares outstanding
50.0m
Valuation (TTM | estimate)
P/E
negative | 29.2
P/S
8.7 | 5.8
EV/Sales
7.2 | 4.8
EV/FCF
14.5
P/B
3.4
Financial Health
Equity Ratio
49.6%
Return on Equity
-32.1%
ROCE
-16.1%
ROIC
-29.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$65.3m | $97.7m
EBITDA
$-44.2m | -
EBIT
$-50.2m | $-26.2m
Net Income
$-58.3m | $19.5m
Free Cash Flow
$32.5m
Growth (TTM | estimate)
Revenue
6.2% | 51.8%
EBITDA
-15.6% | -
EBIT
-21.9% | 38.2%
Net Income
-30.3% | 134.6%
Free Cash Flow
276.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-67.7% | -
EBIT
-76.9%
Net
-89.4% | 20.0%
Free Cash Flow
49.8%
More
EPS
$-1.2
FCF per Share
$0.7
Short interest
13.4%
Employees
97
Rev per Employee
$660.0k
Show more

Is Theravance Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Theravance Biopharma Inc forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Theravance Biopharma Inc forecast:

Buy
73%
Hold
27%

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
65 65
6% 6%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 71 71
5% 5%
108%
- Research and Development Expense 40 40
15% 15%
61%
-44 -44
16% 16%
-68%
- Depreciation and Amortization 5.97 5.97
106% 106%
9%
EBIT (Operating Income) EBIT -50 -50
22% 22%
-77%
Net Profit -58 -58
30% 30%
-89%

In millions USD.

Don't miss a Thing! We will send you all news about Theravance Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theravance Biopharma Inc Stock News

Neutral
Seeking Alpha
about 6 hours ago
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Rhonda F. Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Rick E.
Neutral
PRNewsWire
about 9 hours ago
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year 1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of TRELEGY ELLIPTA royalty interest to GSK for $225 million TRELEGY year-to-date sales on track to trigger $50 million milestone in 2025 Strong balance sheet with $339 million in cash and no debt DUBL...
Neutral
PRNewsWire
16 days ago
DUBLIN , July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tuesday, August 12, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT / 9:00 pm GMT) that day.
More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office Cayman Islands
CEO Rick Winningham
Employees 97
Founded 2013
Website www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today